Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


More Than 1.2m Adverse Drug Reactions Reported In EU In 2016; EMA Reviewed 2,000 Safety Signals

Executive Summary

The European Medicines Agency has published details of the drug safety issues it dealt with in 2016, noting that more than 1.2 million adverse drug reaction reports were received and that it reviewed in excess of 2,000 potential safety signals. A total of 118 products were withdrawn from European markets.

You may also be interested in...

Roadmap To Improve EMA’s Medical Literature Monitoring Service Due Soon

A roadmap to improve the European Medicines Agency’s medical literature monitoring service will be published soon. While some of industry’s suggestions to expand or improve the service have been rejected, many others have either already been implemented or will materialize in the near future.

New EudraVigilance System To Usher In Simplified Reporting of ADRs From Nov. 22

The European Medicines Agency is asking drug companies and EU national competent authorities to prepare for the late November launch of the new EU pharmacovigilance database, which will have enhanced functionalities for reporting and analysing suspected adverse reactions.

BioIndustry Association Slams New UK Guidance On Batch Testing

The UK life sciences trade group says the “ill-considered” guidance will result in duplicative and costly repetition and dent industry’s confidence in the government’s competence.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts